Videos

Retina specialists review new and emerging treatments in neovascular AMD and DME, highlighting high-dose aflibercept and KSI-301.

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao comment on loading dose recommendations for faricimab or other anti-VEGF therapies in the treatment of DME.

Dr Jennifer Lim presents two case studies demonstrating the application of the personalized treatment interval algorithm from the YOSEMITE and RHINE clinical trials for faricimab in DME.

Dr Jennifer Lim reviews the personalized treatment algorithm in the YOSEMITE and RHINE trials for faricimab in DME, discussing visual and anatomic outcomes with the treat and extend strategy.

Retina experts discuss the benefits of using intraocular steroids to treat patients with DME as well as their approach to switching to steroids after a poor response to anti-VEGF therapy.

Expert retina specialists provide an overview of the YOSEMITE and RHINE clinical studies of faricimab in the treatment of DME.

Carl Regillo, MD, FACS, FASRS, and Prethy Rao, MD, MPH, discuss the phase 3 trials of faricimab in the treatment of DME and highlighting the enhanced resolution of intraocular fluid.

Nathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, review the challenges presented in the management of DME, including the disease burden on the patient.

Retina experts discuss biomarkers to track disease progression in neovascular AMD, as well as their thoughts on the utility of optical coherence tomography angiography (OCT-A).

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao share their approaches to dosing recommendations for faricimab in the treatment of neovascular AMD.

Expert retina specialists review the safety profile of faricimab compared with other anti-VEGF therapies in AMD.

Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, discuss patient selection for faricimab in neovascular AMD, as well as approaches to switching to faricimab after a poor response to other treatment.

Expert retina specialists discuss the use of faricimab and dosing for the treatment of neovascular age-related macular degeneration in the clinical practice setting.

Drs Nathan Steinle, Adrienne Scott, and Carl Regillo comment on the phase 3 trial outcomes of faricimab in neovascular AMD.

Leo P. Semes, OD, shared his insights on early detection of age-related macular degeneration during the 17th annual Controversies in Modern Eye Care symposium in Los Angeles, California.

David S. Boyer, MD, senior partner at Retina Vitreous Associates Medical Group, shares key takeaways from "Advances in geographic atrophy," which he co-presented.

Retina experts discuss treatment of wet AMD, focusing on frequency of treatment and treatment breaks, and fluid tolerance.

Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, provide an overview of the effect of anti-VEGF treatment in neovascular age-related macular degeneration and diabetic macular edema.

Roger Goldberg, MD, MBA, spoke with Ophthalmology Times® to share insights about macular leakage area in the YOSEMITE and RHINE trials comparing faricimab to aflibercept.

Michael Ip, MD, highlighted the results of the 5 year follow-up of the original SCORE2 dataset from the NIH-sponsored clinical trial.

Allen Chiang, MD, discussed the assessment of geographic atrophy progression from the Phase 3 OAKS and DERBY trials with our team at the 2023 ARVO annual meeting.

Christine Kay, MD, discussed research for the treatment of GUCY2D associated Leber congenital amaurosis type 1 at this year's ARVO meeting held in New Orleans.

Caroline Baumal, MD, spoke with our onsite team at the 2023 ARVO annual meeting to share more about Apellis' presentations focusing on visual function, imaging and artificial intelligence.

Dierck Hillmann, PhD, was interviewed by our onsite team at the 2023 ARVO annual meeting where he shared research on holographic optical coherence tomography (OCT).

Theresa Heath, MD, MBA, spoke with our onsite team at this year's ARVO annual meeting in New Orleans where she shared insights regarding Non-viral gene therapy targeting ABCA4 retinopathies.

Kaushal Solanki, PhD, CEO and founder of Eyenuk, shared news about the company's EyeArt AI, which is cleared by the FDA to detect diabetic retinopathy.

Our onsite team spoke with Bruce Ksander, PhD, at the 2023 ARVO annual meeting, where he discussed his presentation about epigenetic reprogramming to reverse aging and restore function to retinal ganglion cells.

Edmund Arthur, OD, PhD, FAAO, shared how retinal imaging can be an important tool for early detection of diabetic retinopathy in underserved communities.